Article Dans Une Revue Cancer Management and Research Année : 2019

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

Résumé

The decision to administer adjuvant chemotherapy in treatment of early invasive breast cancer (EBC) is often complex, particularly for hormone receptor-positive (HR+) diseases, and current guidelines often classify these patients in an intermediate-risk group. Several biomarkers are currently available in this indication, in order to obtain additional and more accurate prognostic information compared to classic clinicopathological characteristics and guide the indication of adjuvant chemotherapy, optimizing the efficacy/toxicity ratio. We conducted a systematic review to evaluate the clinical validity and clinical utility of five biomarkers (uPA/PAI-1, OncotypeDX®, MammaPrint®, PAM50, and EndoPredict®) in HR+/HER2- EBC, whatever the nodal status. A total of 89 studies met the inclusion criteria. Even though data currently available confirm the clinical validity of these biomarkers, there is a lack of data regarding clinical utility for most of them. Prospective studies in well-defined populations are needed to integrate these biomarkers in a decision strategy.

Fichier principal
Vignette du fichier
Decision-of-adjuvant-systemic-treatment-in-hr-her2-early-i_3_cmar-221676.pdf (540.3 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-02558204 , version 1 (26-05-2021)

Licence

Identifiants

Citer

Marie Alexandre, Aurélie Maran-Gonzalez, Marie Viala, Nelly Firmin, Véronique D’hondt, et al.. Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?. Cancer Management and Research, 2019, Volume 11, pp.10353-10373. ⟨10.2147/CMAR.S221676⟩. ⟨hal-02558204⟩
94 Consultations
166 Téléchargements

Altmetric

Partager

  • More